Looking for our Business Solutions? Click here:CloudQuote APIsContact Us

Starling Oncology, Inc. - Common Stock (STLN)

6.3584
+0.1384 (2.23%)
NASDAQ · Last Trade: Oct 2nd, 4:13 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.220
Open6.360
Bid6.350
Ask6.360
Day's Range6.220 - 6.370
52 Week Range4.850 - 7.130
Volume623,265
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume1,281,786

Chart

News & Press Releases

Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums
By Starling Oncology · Via GlobeNewswire · October 1, 2026
Starling Oncology to Participate in Wells Fargo Healthcare Conference
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m. ET.
By Starling Oncology · Via GlobeNewswire · August 24, 2026
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow
By Starling Oncology · Via GlobeNewswire · August 17, 2026
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.
By Starling Oncology · Via GlobeNewswire · August 6, 2026